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To assess clinical characteristics, distribution of disease-modifying treatments (DMTs), and
neuropsychological symptoms in a large cohort of patients with early-stage MS.
Methods
The German National MS Cohort is a multicenter prospective longitudinal cohort study that
has recruited DMT-naive patients with clinically isolated syndrome (CIS) and relapsing-
remitting MS (RRMS) since 2010. We evaluated their baseline characteristics and the preva-
lence of neuropsychological symptoms.
Results
Of 1,124 patients, with a 2.2:1 female-to-male ratio and median age at onset of 31.71 years
(interquartile range [IQR]: 26.06–40.33), 44.6% and 55.3% had CIS and RRMS, respectively.
The median Expanded Disability Status Scale (EDSS) score at baseline was 1.5 (IQR: 1.0–2.0). A
proportion of 67.8% of patients startedDMT after a median time of 167.0 days (IQR 90.0–377.5)
since the ﬁrst manifestation. A total of 64.7% and 70.4% of the 762 patients receiving early DMT
were classiﬁed as CIS and RRMS, respectively. Fatigue, depressive symptoms, and cognitive
dysfunction were detected in 36.5%, 33.5%, and 14.7% of patients, respectively.
Conclusion
Baseline characteristics of this large cohort of patients with early, untreated MS corroborated
with other cohorts. Most patients received early DMT within the ﬁrst year after disease onset,
irrespective of a CIS or RRMS diagnosis. Despite the low EDSS score, neuropsychological
symptoms aﬀected a relevant proportion of patients.
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Health insurance data of 2010 revealed that 199,505 patients
have MS in Germany, resulting in a prevalence of 289/
100,000 inhabitants.1 More current epidemiological data from
Germany, however, are scarce.
For a broad spectrum of disease-modifying treatments
(DMTs), data of phase III trials on safety and eﬃcacy with
selected populations can only partly be transferred to real-
world settings.2 Published studies may be outdated at the time
of publication in a rapidly changing DMT landscape. In an
observational study, the time from the onset of clinically
isolated syndrome (CIS) to DMT varied from 15.2 months,
for patients recruited during the 2002–2007 period, to 41.5
months, for those recruited during the 1995–2001 period.3
Compared with more recent data (61.6%),4 the proportion of
patients receiving DMT (38.3%) was low.
The prevalence of comorbidity in MS varies considerably.5
Compared with the reported prevalence of fatigue in
population-based samples (6.1%–30.5%),6,7 that in MS
ranges from 31.3% to 81%.8–11 Similarly, the reported prev-
alence of depression in MS ranges from 6.9% to 70.1%12 and
from 3.8% to 10.2% in the German population.13 Cognitive
decline is reportedly prevalent in MS (43%–70%).14 The
estimated prevalence of mild cognitive impairment at the age
of 60 years or above is 5.9%.15 Taken together, these ﬁndings
indicate that premature aging of the brain alone cannot
explain the high prevalence of cognitive impairment in MS.
Data on associations of fatigue, depression, cognitive decline,
and physical disability depict varying results.16,17 The
discrepancies in both the prevalence and associations of these
domains may have various causes: many cohorts are small,
there is a variation in assessment tools, and MS populations
were diﬀerently selected (or unselected).8–10,14
The aim of this studywas to assess clinical characteristics of a large
cohort of patients with CIS or early relapsing-remitting MS
(RRMS), DMT behavior, and neuropsychological symptoms.
Methods
Standard protocol approvals, registrations,
and patient consents
This multicenter prospective longitudinal observational co-
hort study (German National MS Cohort) was approved by
the ethics committee of Ruhr-University Bochum (registra-
tion no. 3714-10), and consecutively, all local committees of
the participating centers (22 centers in Germany). All patients
provided written informed consent.
Inclusion and exclusion criteria
and recruitment
Table 1 outlines the inclusion and exclusion criteria. A total of
1,212 patients were recruited and included between August
2010 and December 2014.
Assessment plan
Patient visits were scheduled annually until year 2 and sub-
sequently every other year for 10 years. Table 2 outlines the
Table 1 Inclusion and exclusion criteria of the German National MS Cohort
Inclusion criteria Exclusion criteria
1) Age ≥18 yrs; male and female 1) Previous use of DMT (irrespective of administered short-
term relapse treatment)
2a) Diagnosis of CIS within 6 mo before inclusion—fulfilling 3 of 4 Barkhof criteria33 2) PPMS and other progressive forms of MS
OR—fulfilling 2 of 4 Barkhof criteria33 with supportive findings in CSF (intrathecal IgG
production/oligoclonal bands) or in VEP
3) Concurrent progressive neurologic diseases
OR—fulfilling RRMS diagnosis based on McDonald criteria 201029 4) Conditions interfering with the assessment plan (e.g.,
general contraindication for MRI)
Alternatively
2b) Diagnosis of RRMS based on McDonald criteria 200534 within 2 yrs before inclusion
Abbreviations: CIS = clinically isolated syndrome; DMT = disease-modifying treatment; PPMS = primary progressiveMS; RRMS = relapsing-remittingMS; VEP =
visual evoked potential.
Glossary
BDI-II = Beck Depression Inventory II; BMI = body mass index; CI = conﬁdence interval; CIS = clinically isolated syndrome;
DMT = disease-modifying treatment; EDSS = Expanded Disability Status Scale; FSMC = Fatigue Scale for Motor and
Cognitive Functions; IQR = interquartile range; MSFC = Multiple Sclerosis Functional Composite; MUSIC = Multiple
Sclerosis Inventory of Cognition; RRMS = relapsing-remitting MS.
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detailed assessment plan. The centers consented to all the
included parameters before the initiation of the study. If
available, well-established international scales, such as the
Expanded Disability Status Scale (EDSS)18 or the Multiple
Sclerosis Functional Composite (MSFC),19 were imple-
mented. For neuropsychological measurements, scales that
were already implemented in routine assessments in some or
most of the centers were preferentially chosen. Minimal, mild,
moderate, or severe degree of symptoms were deﬁned
according to the respective test manual.
Statistical analysis
Descriptive statistics summarized baseline measurements. We
deﬁned the medians and interquartile ranges (IQRs) of
continuous variables and absolute and relative frequencies of
categorical variables. Explorative correlation analyses (without
multiple testing correction) were performed using Kendall’s tau-
b with 95% CIs, which were constructed using 2000 bootstrap
samples to determine convergent and discriminant validity
relationships. All analyses were performed using statistical soft-
ware R version 3.3.0 (R Foundation, Vienna, Austria).
Handling of missing values and items
Missing values were reported for each parameter throughout the
analyses. For the Fatigue Scale for Motor and Cognitive Func-
tions (FSMC)20 and Beck Depression Inventory II (BDI-II)21
patient questionnaires, missing items were handled as follows:
missing items were imputed usingmean imputation, if 3 items, at
most, weremissing; if more than 3 itemsweremissing, the whole
questionnaire was classiﬁed as a missing value.
Results
Clinical and demographic characteristics of
the cohort
After data monitoring, 1,124 baseline data sets were suﬃcient
for analysis. Of 1,124 patients, 44.6% were diagnosed with
CIS and 55.3% with RRMS at inclusion (ﬁgure 1A). The sex
distribution was a female-to-male ratio of 2.2:1 (ﬁgure 1B).
Table 3 outlines the patient characteristics at baseline.
At baseline, the median EDSS18 score was 1.5 (IQR: 1.0–2.0,
table 3), with 23 patients (2.0%) demonstrating an EDSS
score of 4.0 or higher. The EDSS score ranged from 0 to 6.0,
in total, within this visit. The initial presentation was mono-
symptomatic in 74.0% of the cohort. Figure 1C further
characterizes these issues.
Disease-modifying treatment
A total of 67.8% of patients started DMT after a median time of
167.0 days (IQR: 90.0–377.5) after the ﬁrst manifestation. In
the treated population, 324 patients had CIS, while 438 had
RRMS, resulting in a frequency of 64.7% and 70.4% of patients
with CIS and RRMS, respectively, receiving DMT. Dissecting
time intervals from the ﬁrst manifestation to DMT initiation for
diagnosis, the median interval for the CIS group was 107.0 days
(IQR: 72.0–212.0), but 242.0 days (IQR: 120.0–466.0) for the
RRMS group. By contrast, themedian interval from diagnosis of
RRMS to DMT initiation was 88.0 days (IQR: 52.0–167.0).
Table 4 outlines the distribution of DMT, demonstrating
a proportion of 80.2% with established injectables (interferon-β
or glatiramer acetate). This proportion was slightly higher in the
CIS group (87.0%). Nevertheless, a small proportion of patients
were early treated with highly active agents, such as alemtuzu-
mab, ﬁngolimod, mitoxantrone, natalizumab, and even oﬀ-label
rituximab, as their ﬁrst-line therapy (table 4).
Neuropsychological findings
Table 5 shows the results of the neuropsychological
assessments at baseline. Despite the overall low EDSS score
in this cohort, approximately 36.5% of patients reported at
Table 2 Assessment plan of the German National MS
Cohort
Data obtained/updated in every visit
1) Sociodemographic data
Age, sex, and ethnicity
Education, employment status, and social situation
2) General medical history and examination
Concomitant diseases, allergies, and medication
BMI (kg/m2), blood pressure, heart rate, and physical examination
Smoking status (no, occasionally, regularly [up to 5, 6–10, 11–20, and >20],
and unknown)
Alcohol use (no, occasionally, regularly, and unknown)
Family history
3) MS disease history
Date of onset, date of diagnosis, and diagnostic criteria
Symptoms of the first attack
Detailed relapse assessment including relapse treatment
4) Neurologic status and assessments
Expanded Disability Status Scale (EDSS)18
Multiple Sclerosis Functional Composite (MSFC)19
Multiple Sclerosis Inventory of Cognition (MUSIC)22
5) Patient questionnaires (self-reported)
Fatigue Scale for Motor and Cognitive Functions (FSMC)20




Standardized collection of biomaterial (plasma, serum, DNA, RNA, in
subsets: PBMC, CSF)
Abbreviations: BMI = body mass index; PBMC = peripheral blood mono-
nuclear cell.
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least mild symptoms of fatigue. Almost a quarter of patients
reported moderate fatigue, whereas 13.5% of patients
reported severe fatigue at these early stages of the disease.
Furthermore, approximately 33.5% of patients showed, “At
least minimal depressive symptoms,” which were deﬁned
by 9 or more points in BDI-II. A total of 14.7% of patients
exhibited detectable neurocognitive deﬁcits with the ap-
plied screening battery.
Explorative correlation analyses
Physical disability was measured using the EDSS, whereas
neuropsychological ﬁndings were measured using the FSMC,
BDI-II, and Multiple Sclerosis Inventory of Cognition
(MUSIC).22 Table 6 outlines the results of the explorative
correlation analyses between physical disability and neuro-
psychological scales.
EDSS only showed weak correlations to fatigue, depression,
and cognitive performance (table 6 and ﬁgure e-1, A–C, links.
lww.com/NXI/A38). Cognitive performance, as measured
with the MUSIC screening test, and depression were not
correlated (table 6). Fatigue and depression were moder-
ately correlated (Kendall’s tau-b: 0.55 [0.52–0.58], table 6,
ﬁgure e-2A, links.lww.com/NXI/A38). The positive correla-
tion between the FSMC (total score) and BDI-II persisted
even after the exclusion of overlapping questions from the
Figure 1 Characteristics of the German National MS Cohort
(A) Diagnosis at inclusion, n = 1 missing value, (B) sex distribution, and (C) first symptom at disease onset: monosymptomatic vs polysymptomatic and
distribution according to EDSS functional systems. CIS = clinically isolated syndrome; EDSS = ExpandedDisability Status Scale; RRMS = relapsing-remittingMS.
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BDI-II (Kendall’s tau-b after exclusion: 0.46 [0.42–0.49],
ﬁgure e-2B, links.lww.com/NXI/A38).
Finally, with the low EDSS score at this early stage of disease,
it was poorly correlated with body mass index (BMI) (Ken-
dall’s tau-b: 0.12 [0.07–0.16], table 6).
Discussion
This comprehensive analysis describes patients in the early
stages of MS in the largest German prospective MS cohort
from 22 academic centers. The main ﬁnding of the current
study was the frequent early occurrence of fatigue, depressive
symptoms, and cognitive dysfunction, which was observed in
36.5%, 33.5%, and 14.7% of patients, respectively. This
underscores that MS greatly aﬀects nonmotor symptoms and
the quality of life, even at its early stages.
The median age of 31.71 years at disease onset is consistent
with previous publications.23 However, given the inclusion
criteria of this prospective study with the aim of a well-
controlled uniform cohort for long-term follow-up, only
Table 3 Baseline demographic data of the German National MS Cohort
Age at inclusion (yrs) (median, IQR) 32.40 (26.55–40.98)
Age at the first manifestation/CIS (yrs) (median, IQR) 31.71 (26.06–40.33)
Disease duration at baseline—whole group (yrs) (median, IQR)a 0.33 (0.20–0.70)
Disease duration at baseline—only CIS (yrs) (median, IQR)a 0.24 (0.17–0.37)
Disease duration at baseline—only RRMS (yrs) (median, IQR)a 0.51 (0.25–1.15)
Age at RRMS diagnosis—only RRMS (yrs) (median, IQR) 31.67 (26.50–40.33)
Time from RRMS diagnosis at baseline—only RRMS (yrs) (median, IQR) 0.17 (0.11–0.31)
EDSS at baseline, available for n = 1,121 patients (median, IQR) 1.5 (1.0–2.0)
BMI at baseline (kg/m2), available for n = 1,101 patients (median, IQR) 24.22 (21.63–27.66)
Smoking behavior (“ever-smoking”), available for n = 1,102 patients (n, %) 366 (33.2%)
Alcohol consumption (“ever-consuming”), available for n = 1,105 patients (n, %) 812 (73.5%)
Abbreviations: BMI = bodymass index; CIS = clinically isolated syndrome; EDSS= ExpandedDisability Status Scale; IQR = interquartile range; RRMS = relapsing-
remitting MS.
a Disease duration defined as the time from the first manifestation to baseline. Data were available for all 1,124 patients, unless otherwise indicated.
Table 4 First disease-modifying treatments (DMTs) in the German National MS Cohort
Disease-modifying treatment All patients: frequency, n (%) CIS: frequency, n (%) RRMS: frequency, n (%)
Study medication (blinded) 2 (0.3) 0 (0.0) 2 (0.5)
Alemtuzumab 3 (0.4) 0 (0.0) 3 (0.7)
Azathioprine 2 (0.3) 2 (0.6) 0 (0.0)
Dimethyl fumarate and other fumaric acid formulations 79 (10.4) 23 (7.1) 56 (12.8)
Fingolimod 22 (2.9) 5 (1.5) 17 (3.9)
Glatiramer acetate 178 (23.3) 80 (24.7) 98 (22.4)
Interferon-β formulations 434 (56.9) 202 (62.3) 231 (52.7)
Mitoxantrone 1 (0.1) 0 (0.0) 1 (0.2)
Natalizumab 27 (3.5) 6 (1.9) 21 (4.8)
Rituximab 1 (0.1) 0 (0.0) 1 (0.2)
Teriflunomide 14 (1.8) 6 (1.9) 8 (1.8)
Total 763 patients 324 patients 438 patients
Abbreviations: CIS = clinically isolated syndrome; RRMS = relapsing-remitting MS.
DMT is listed in alphabetical order. Because of 1 missing value in diagnosis at inclusion (figure 1), there is a discrepancy in the interferon-β group.
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recently diagnosed adult patients were enrolled. Thus, the
current study could not analyze the spectrum of childhood-
onset MS or progressive forms of the disease. The female
preponderance (2.2:1 female-to-male ratio) is in accord with
published data.4,11,23
Disease onset was mainly monosymptomatic, with sensory or
visual symptoms being the most prevalent. This is in line with
data demonstrating that visual and sensory symptoms typi-
cally occur early during the disease course and preferentially
aﬀect younger and female patients.24 This may also have
implications for recovery from relapse.24
In the current cohort, EDSS revealed a generally low physical
disability (median EDSS: 1.5) because of early inclusion of
patients. Nevertheless, 2.0% of the cohort already exhibited
severe impairment (EDSS: ≥4.0) at early disease stages. Be-
cause this analysis only depicts baseline data, we cannot ex-
clude primarily relapse-driven disability at this time point that
may not be conﬁrmed during follow-up as sustained disability.
Nevertheless, this might reﬂect disease heterogeneity with
milder vs more severe initial symptoms and highly aggressive
disease onset in a low percentage of patients.
BMI, especially adolescent obesity, which is an inﬂuencing
factor of disease susceptibility, could aﬀect disease severity
and progression.25,26 Although the median BMI in the current
cohort was 24.22 kg/m2 (IQR: 21.63–27.66), 15.1% of
patients had a BMI of 30 kg/m2 or higher. There was only
a poor correlation between BMI and physical disability
(i.e., the EDSS), which might change with further observation
of the cohort. Smoking (ever smoking 33.2%) showed
a comparable prevalence in the general German population.27
Table 5 Results of neuropsychological assessments at baseline: Symptom frequencies by severity
Test battery Degree of severity Frequency, n (%)
FSMC—total score, available for n = 1,069 patients At least mild fatigue (>42 Pt.) 390 (36.5)
At least moderate fatigue (>52 Pt.) 261 (24.4)
Severe fatigue (>62 Pt.) 144 (13.5)
FSMC—cognitive fatigue, available for n = 1,069 patients At least mild fatigue (>21 Pt.) 375 (35.1)
At least moderate fatigue (>27 Pt.) 226 (21.1)
Severe fatigue (>33 Pt.) 116 (10.9)
FSMC—motor fatigue, available for n = 1,069 patients At least mild fatigue (>21 Pt.) 410 (38.4)
At least moderate fatigue (>26 Pt.) 273 (25.5)
Severe fatigue (>31 Pt.) 155 (14.5)
BDI-II, available for n = 1,073 patients At least minimal (>8 Pt.) 359 (33.5)
At least mild (>13 Pt.) 185 (17.2)
At least moderate (>19 Pt.) 88 (8.2)
Severe (>28 Pt.) 27 (2.5)
MUSIC, available for n = 1,064 patients At least mild (<20 Pt.) 157 (14.7)
At least moderate (<16 Pt.) 60 (5.6)
Severe (<11 Pt.) 8 (0.8)
Abbreviations: BDI-II = Beck Depression Inventory II; FSMC = Fatigue Scale for Motor and Cognitive Functions; MUSIC = Multiple Sclerosis Inventory of
Cognition; Pt. = points.
Table 6 Explorative correlation analyses
Variables Kendall’s tau (CI)
FSMC total score vs EDSS 0.24 (0.20 to 0.29)
FSMC motor fatigue vs EDSS 0.25 (0.21 to 0.29)
FSMC cognitive fatigue vs EDSS 0.22 (0.17 to 0.26)
FSMC total score vs BDI-II 0.55 (0.52 to 0.58)
FSMC motor fatigue vs BDI-II 0.53 (0.50 to 0.56)
FSMC cognitive fatigue vs BDI-II 0.54 (0.51 to 0.57)
BDI-II vs EDSS 0.20 (0.16 to 0.25)
MUSIC vs EDSS −0.13 (−0.17 to −0.08)
MUSIC vs BDI-II −0.10 (−0.14 to −0.06)
BMI vs EDSS 0.12 (0.07 to 0.16)
Abbreviations: BDI-II = Beck Depression Inventory II; BMI = bodymass index;
EDSS = ExpandedDisability Status Scale; FSMC = Fatigue Scale forMotor and
Cognitive Functions; MUSIC = Multiple Sclerosis Inventory of Cognition.
6 Neurology: Neuroimmunology & Neuroinflammation | Volume 5, Number 3 | May 2018 Neurology.org/NN
It inﬂuences the acceleration of disease course with 1.34 and
1.25 times higher odds of reaching EDSS scores of 4.0 and 6.0,
respectively.28
More than two-thirds of patients in our cohort received DMT,
which was comparable with the MSBase data set.4 Because
recruitment mostly occurred via academic centers, however,
this might produce a selection bias, and thus, the data might
not be representative of the general German population.
Moreover, progressive forms of disease were not included.
The patients in the current cohort started treatment only
recently, and thus, it would be premature to draw conclusions
on adherence. Given the broad access to medical supply in the
German health care system, the frequency of DMT for
patients with CIS (64.7%) and RRMS (70.4%) was quite
similar to the current cohort. Yet, the interval from the ﬁrst
manifestation to DMT initiation diﬀered; the median interval
was 107.0 days (IQR: 72.0–212.0) for patients with CIS,
whereas it was 242.0 days (IQR: 120.0–466.0) for those with
RRMS. By contrast, the interval from diagnosis of RRMS to
DMT initiation was markedly shorter (88.0 days [IQR:
52.0–167.0]). A possible explanation for this ﬁnding is that
patients were enrolled in centers that were experienced with
MS diagnosis and treatment. Therefore, it is more likely that
patients who were diagnosed with CIS and RRMS in the
center were counseled to initiate DMT early. For RRMS, it is
possible that the ﬁrst manifestation did not even lead to
a medical consultation or consultation in a nonspecialized
setting, which might aﬀect the timing of treatment initiation.
All our reported intervals were still much shorter than in
a large previous analysis, which started 15 years earlier than
this cohort.3 This might partly be explained by changes in
diagnostic criteria over time because parts of our CIS cohort
will putatively already fulﬁll McDonald criteria 201029 for
RRMS. Again, we cannot exclude a center bias. A further
general change in MS treatment paradigms toward an earlier
treatment initiation in the last decade has to be discussed as
well. The overall treatment distribution comprised 80.2% of
treated patients with interferon-β formulations or glatiramer
acetate. Yet, in line with the notion that patients with ag-
gressive disease onset and high EDSS at baseline were en-
rolled, there were patients receiving highly active DMT as the
ﬁrst treatment. It must be noted that patients diagnosed with
CIS but treated with oral DMTs by the independent neu-
rologist may already fulﬁll diagnostic criteria according to the
McDonald 2010 revisions.29 Lower frequencies of more active
DMT might reﬂect a prevailing DMT paradigm of escalation
rather than induction in most patients. It must also be noted
that DMTs such as alemtuzumab, for instance, which may
qualify for induction strategies, were only available at the end
of the recruitment period.
Neuropsychological symptoms in this early MS cohort af-
fected a relevant proportion of patients: At baseline, 36.5%
and 24.4% of patients reported at least mild and moderate
fatigue symptoms, respectively, despite the low physical dis-
ability measured by EDSS. However, the prevalence rates of
fatigue in MS are still hardly comparable between published
cohorts, given the considerable variation in assessment
instruments.8–10 The FSMC is currently possibly the most
suitable tool to assess fatigue in MS.20 Because our cohort is
an early, well-deﬁned cohort with regular follow-up, the
evolution of fatigue can be thoroughly assessed over time.
Similarly, we can also study its longitudinal relationship with
depression and cognitive function. The pathophysiology of
fatigue in MS may include both autoimmune inﬂammatory
processes associated with myelin and axonal damage and
factors such as sleep disturbance, vigilance regulation, de-
pression, inactivity, disability status, and side eﬀects of
medication.10,30 Our study may help to further elucidate these
factors as MRI and laboratory dates become available. The
interaction of fatigue and depression, which, like in other
studies, correlated, even after controlling for fatigue con-
taminated items of the BDI must at this stage be cautiously
interpreted as we did not yet control for confounding factors.
One might argue about the clinical relevance of minimal
symptoms of depression that were present in 33.4% of
patients. This percentage might partly reﬂect the early ad-
justment processes to the diagnosis. However, depression
rates might indicate a response to chronic illness or even
a speciﬁc trait related to MS immunopathology.12 Psycho-
logical interventions should be available for the relevant
proportion of 17.2% of patients with mild or more severe
depression.
The large data set of our cohort demonstrated that 14.7% of
the patients displayed cognitive dysfunction detectable with
a screening instrument. Because MUSIC has only been vali-
dated inGerman, comparative data to other neuropsychological
batteries are missing thus far. This represents a major limitation
to the study. However, it covers major cognitive impairment
domains in MS in a 20-minute examination. As expected, the
prevalence of cognitive decline in unselectedMS populations is
higher.14 There is a current scientiﬁc discussion on whether
cognitive symptoms appear before the ﬁrst clinical MS symp-
toms as an indicator of diﬀuse brain damage.31 However, the
prevalence and evolution of cognitive dysfunction, as well as the
inﬂuence of DMT on this domain in MS, are still poorly un-
derstood. Thus, further longitudinal data sets are warranted.
Early focused neurocognitive assessment is crucial to recognize
early cognitive symptoms, especially in terms of long-term
treatment evaluations to assess possible eﬀects on clinically
relevant cognitive functioning over time.
In contrast to previous data,32 the applied battery of tests
did not reveal an association between depression and
cognition in the current study. This might be due to the
mild severity of both or be attributed to a short disease
duration with preserved cognition leading to patients with
depression still performing well in cognitive screening. Yet,
this needs to be cautiously discussed because these ﬁrst
analyses were not controlled for confounders at this stage
and the MUSIC battery has not been evaluated in this
context before.
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Furthermore, similar to fatigue and depression, MUSIC
results poorly correlated with EDSS, with respect to the
caveats mentioned above. This corroborated with previous
investigations22 and underlines the weakness of the EDSS in
detecting these domains. This also highlights the need for
distinct assessments in the early stages of MS.
Baseline data of this large multicenter cohort provide an im-
portant insight into early MS. Relevant demographic data
were prospectively conﬁrmed for a German population for the
ﬁrst time, and the distribution of DMTs was elucidated.
Neuropsychological comorbidities, which can be detected
with screening batteries, seem relevant in the earliest stages of
MS. Because they aﬀect a large proportion of patients, but are
not reﬂected by EDSS, distinct routine clinical assessment of
these neuropsychological comorbidities is an unmet need in
patient care. This may also have therapeutic implications.
Although, thus far, neuropsychiatric interventions in MS are
not highly developed, increased awareness and assessment
sensitivity for a clinically relevant symptomatology could
further help treatment development.
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